Literature DB >> 19907340

Repair of necrotizing scleritis in ulcerative colitis with processed pericardium and a Prokera amniotic membrane graft.

Douglas R Lazzaro1.   

Abstract

OBJECTIVES: To demonstrate an unusual case of necrotizing scleritis in ulcerative colitis successfully managed by a combination of a Prokera implant and processed pericardium.
METHODS: A case report of a novel approach to treat scleral melts that may be seen in several clinical situations.
RESULTS: The dual use of amniotic membrane material (Prokera) with processed tuttoplast for necrotizing scleritis salvaged the eye without the need for enucleation while also preserving most of the vision.
CONCLUSIONS: Consideration of the combined method discussed in this article should be considered in the treatment of severe scleromalacia seen in inflammatory cases of the eye.

Entities:  

Mesh:

Year:  2010        PMID: 19907340     DOI: 10.1097/ICL.0b013e3181c6deb0

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  4 in total

1.  Use of autologous fascia lata as a natural biomaterial for tectonic support in surgically induced necrotizing scleritis.

Authors:  H Kobtan
Journal:  Eye (Lond)       Date:  2015-01-30       Impact factor: 3.775

2.  Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.

Authors:  Anny M S Cheng; Dandan Zhao; Rendian Chen; Han Y Yin; Sean Tighe; Hosam Sheha; Victoria Casas; Scheffer C G Tseng
Journal:  Ocul Surf       Date:  2015-09-24       Impact factor: 5.033

3.  Preserved Corneal Lamellar Grafting Reduces Inflammation and Promotes Wound Healing in a Scleral Defect Rabbit Model.

Authors:  Kyoung Woo Kim; Jin Suk Ryu; Jun Yeob Kim; Mee Kum Kim
Journal:  Transl Vis Sci Technol       Date:  2020-06-29       Impact factor: 3.283

4.  The usability of lamellar scleral autograft in ocular perforation treatment.

Authors:  Umut Karaca; Gulsah Usta
Journal:  Int Ophthalmol       Date:  2021-06-26       Impact factor: 2.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.